According to a recent LinkedIn post from Francis Medical, the company is present alongside the urology community at the European Association of Urology Congress 2026 in London. The post highlights the EAU26 Prostate Cancer Run, where clinicians participate in a walk or run focused on prostate cancer awareness and engagement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also notes that Francis Medical’s technology is FDA cleared and directs readers to its website for information about the company and safety details. For investors, visible participation in a major specialty congress and alignment with prostate cancer advocacy may support brand recognition among urologists, potentially strengthening long‑term commercial adoption prospects in the prostate cancer treatment market.